Research ExplorerPublicationsCirculating tumour cell-derived plastin3 is a novel marker f...

Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer

Standard

Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer. / Ueo, H; Sugimachi, K; Gorges, T M; Bartkowiak, K; Yokobori, T; Müller, V; Shinden, Y; Ueda, M; Ueo, H; Mori, M; Kuwano, H; Maehara, Y; Ohno, S; Pantel, K; Mimori, K.

In: BRIT J CANCER, Vol. 112, No. 9, 28.04.2015, p. 1519-26.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Ueo, H, Sugimachi, K, Gorges, TM, Bartkowiak, K, Yokobori, T, Müller, V, Shinden, Y, Ueda, M, Ueo, H, Mori, M, Kuwano, H, Maehara, Y, Ohno, S, Pantel, K & Mimori, K 2015, 'Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer', BRIT J CANCER, vol. 112, no. 9, pp. 1519-26. https://doi.org/10.1038/bjc.2015.132

APA

Ueo, H., Sugimachi, K., Gorges, T. M., Bartkowiak, K., Yokobori, T., Müller, V., Shinden, Y., Ueda, M., Ueo, H., Mori, M., Kuwano, H., Maehara, Y., Ohno, S., Pantel, K., & Mimori, K. (2015). Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer. BRIT J CANCER, 112(9), 1519-26. https://doi.org/10.1038/bjc.2015.132

Vancouver

Ueo H, Sugimachi K, Gorges TM, Bartkowiak K, Yokobori T, Müller V et al. Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer. BRIT J CANCER. 2015 Apr 28;112(9):1519-26. https://doi.org/10.1038/bjc.2015.132

Bibtex

@article{85d4657e6a0e4a5b8ffd189e119a454c,
title = "Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer",
abstract = "BACKGROUND: Identification of promising biomarkers that predict the prognosis of patients with breast cancer is needed. In this study, we hypothesised that the expression of the epithelial-mesenchymal transition-related biomarker plastin3 (PLS3) in peripheral blood could be a prognostic factor in breast cancer.METHODS: We examined PLS3 expression in breast cancer cell lines with epithelial and mesenchymal traits and in circulating tumour cells (CTCs) obtained from the peripheral blood of breast cancer patients. We investigated PLS3 expression in the peripheral blood of 594 patients with breast cancer to evaluate the clinical significance of PLS3 expression.RESULTS: Robust PLS3 expression was observed in different breast cancer cell lines (Hs578t, MCF-7, MDA-MB-468, and MDA-MB-231) as well as in a bone marrow derived cancer cell line (BC-M1). In both the training (n=298) and validation (n=296) sets, PLS3 expression was observed in CTCs of patients with breast cancer. PLS3-positive patients showed significantly poorer overall and disease-free survival than PLS3-negative patients (P=0.0001 and 0.003, respectively). Subset analysis revealed that this prognostic biomarker was relevant in patients with stage I-III cancer, particularly in patients with luminal-type and triple-negative-type tumours.CONCLUSIONS: These data demonstrated that PLS3 was expressed in CTCs undergoing the epithelial-mesenchymal transition in patients with breast cancer. Furthermore, PLS3 may be an excellent biomarker for identifying groups at risk of recurrence or with a poor prognosis.",
keywords = "Blotting, Western, Breast Neoplasms, Case-Control Studies, Epithelial-Mesenchymal Transition, Female, Follow-Up Studies, Humans, Lymphatic Metastasis, Membrane Glycoproteins, Microfilament Proteins, Middle Aged, Neoplasm Grading, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Neoplasm Staging, Neoplastic Cells, Circulating, Prognosis, RNA, Messenger, Real-Time Polymerase Chain Reaction, Reverse Transcriptase Polymerase Chain Reaction, Survival Rate, Tumor Markers, Biological",
author = "H Ueo and K Sugimachi and Gorges, {T M} and K Bartkowiak and T Yokobori and V M{\"u}ller and Y Shinden and M Ueda and H Ueo and M Mori and H Kuwano and Y Maehara and S Ohno and K Pantel and K Mimori",
year = "2015",
month = apr,
day = "28",
doi = "10.1038/bjc.2015.132",
language = "English",
volume = "112",
pages = "1519--26",
journal = "BRIT J CANCER",
issn = "0007-0920",
publisher = "NATURE PUBLISHING GROUP",
number = "9",

}

RIS

TY - JOUR

T1 - Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer

AU - Ueo, H

AU - Sugimachi, K

AU - Gorges, T M

AU - Bartkowiak, K

AU - Yokobori, T

AU - Müller, V

AU - Shinden, Y

AU - Ueda, M

AU - Ueo, H

AU - Mori, M

AU - Kuwano, H

AU - Maehara, Y

AU - Ohno, S

AU - Pantel, K

AU - Mimori, K

PY - 2015/4/28

Y1 - 2015/4/28

N2 - BACKGROUND: Identification of promising biomarkers that predict the prognosis of patients with breast cancer is needed. In this study, we hypothesised that the expression of the epithelial-mesenchymal transition-related biomarker plastin3 (PLS3) in peripheral blood could be a prognostic factor in breast cancer.METHODS: We examined PLS3 expression in breast cancer cell lines with epithelial and mesenchymal traits and in circulating tumour cells (CTCs) obtained from the peripheral blood of breast cancer patients. We investigated PLS3 expression in the peripheral blood of 594 patients with breast cancer to evaluate the clinical significance of PLS3 expression.RESULTS: Robust PLS3 expression was observed in different breast cancer cell lines (Hs578t, MCF-7, MDA-MB-468, and MDA-MB-231) as well as in a bone marrow derived cancer cell line (BC-M1). In both the training (n=298) and validation (n=296) sets, PLS3 expression was observed in CTCs of patients with breast cancer. PLS3-positive patients showed significantly poorer overall and disease-free survival than PLS3-negative patients (P=0.0001 and 0.003, respectively). Subset analysis revealed that this prognostic biomarker was relevant in patients with stage I-III cancer, particularly in patients with luminal-type and triple-negative-type tumours.CONCLUSIONS: These data demonstrated that PLS3 was expressed in CTCs undergoing the epithelial-mesenchymal transition in patients with breast cancer. Furthermore, PLS3 may be an excellent biomarker for identifying groups at risk of recurrence or with a poor prognosis.

AB - BACKGROUND: Identification of promising biomarkers that predict the prognosis of patients with breast cancer is needed. In this study, we hypothesised that the expression of the epithelial-mesenchymal transition-related biomarker plastin3 (PLS3) in peripheral blood could be a prognostic factor in breast cancer.METHODS: We examined PLS3 expression in breast cancer cell lines with epithelial and mesenchymal traits and in circulating tumour cells (CTCs) obtained from the peripheral blood of breast cancer patients. We investigated PLS3 expression in the peripheral blood of 594 patients with breast cancer to evaluate the clinical significance of PLS3 expression.RESULTS: Robust PLS3 expression was observed in different breast cancer cell lines (Hs578t, MCF-7, MDA-MB-468, and MDA-MB-231) as well as in a bone marrow derived cancer cell line (BC-M1). In both the training (n=298) and validation (n=296) sets, PLS3 expression was observed in CTCs of patients with breast cancer. PLS3-positive patients showed significantly poorer overall and disease-free survival than PLS3-negative patients (P=0.0001 and 0.003, respectively). Subset analysis revealed that this prognostic biomarker was relevant in patients with stage I-III cancer, particularly in patients with luminal-type and triple-negative-type tumours.CONCLUSIONS: These data demonstrated that PLS3 was expressed in CTCs undergoing the epithelial-mesenchymal transition in patients with breast cancer. Furthermore, PLS3 may be an excellent biomarker for identifying groups at risk of recurrence or with a poor prognosis.

KW - Blotting, Western

KW - Breast Neoplasms

KW - Case-Control Studies

KW - Epithelial-Mesenchymal Transition

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Lymphatic Metastasis

KW - Membrane Glycoproteins

KW - Microfilament Proteins

KW - Middle Aged

KW - Neoplasm Grading

KW - Neoplasm Invasiveness

KW - Neoplasm Recurrence, Local

KW - Neoplasm Staging

KW - Neoplastic Cells, Circulating

KW - Prognosis

KW - RNA, Messenger

KW - Real-Time Polymerase Chain Reaction

KW - Reverse Transcriptase Polymerase Chain Reaction

KW - Survival Rate

KW - Tumor Markers, Biological

U2 - 10.1038/bjc.2015.132

DO - 10.1038/bjc.2015.132

M3 - SCORING: Journal article

C2 - 25880010

VL - 112

SP - 1519

EP - 1526

JO - BRIT J CANCER

JF - BRIT J CANCER

SN - 0007-0920

IS - 9

ER -